{"task_id": "fa7e4581d4ed5e25", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 361/464)", "text": "er failure (decreased\nactivation)\n352\nHypocalcemia\n\n--- Page 374 ---\nSPECIFIC ENTITIES (CONT\u2019D)\n\u0002\nCLINICAL FEATURES\nhypocalcemia, hypophospha\ntemia, osteomalacia with associated bone pain,\nosteoporosis with fractures and hyperparathyroid\nism. Vitamin D deficiency has also been postulated\nto be associated with chronic diseases such as\ncancer, cardiovascular diseases, diabetes, autoim\nmune disorders, and osteoarthritis\n\u0002\nDIAGNOSIS\n25 hydroxyvitamin D is used to deter\nmine the level of vitamin D as it represents the\nSPECIFIC ENTITIES (CONT\u2019D)\ncombined level from both dietary and skin sources.\nA level <80 nmol/L is considered to be abnormal\n\u0002\nTREATMENTS\nvitamin D2 50,000 IU per week \u00038\nweeks for most causes; repeat for another 8 weeks\nif 25 hydroxyvitamin D still low. Long term use of\nvitamin D3 800 1000 IU PO daily. For renal failure,\ncalcitriol 0.25 1 mg PO BID should be given\nNEJM 2007 357:3\nHypercalcemia\nDIFFERENTIAL DIAGNOSIS\nHYPERPARATHYROIDISM (most common cause\namong outpatients)\nparathyroid adenoma, para\nthyroid hyperplasia, parathyroid carcinoma (rare)\nMALIGNANCY (most common cause among inpa\ntients)\nlung, breast, prostate, renal, thyroid, GI,\nmelanoma,\nsarcoma,\nmultiple myeloma,\nlym\nphoma, leukemia\nGRANULOMATOUS\nDISEASE\nTB,\nsarcoidosis,\nlymphoma\nENDOCRINE\nAddison\u2019s,\nhyperthyroidism,\nacromegaly\nDRUGS\nvitamin D toxicity, thiazide, lithium,\ntamoxifen\nNUTRITIONAL\ncalcium supplement, vitamin D,\nvitamin A, milk alkali syndrome\nOTHERS\nimmobility, Zollinger Ellison syndrome,\nfamilialhypocalciurichypercalcemia,acuterenalfailure\nPATHOPHYSIOLOGY\nDEFINITION\nOF\nHYPERCALCEMIA\ncorrected\nserum Ca >2.6 mmol/L [10.4 mg/dL]. For every\n10 g/L (1 g/dL) # in albumin, correct serum Ca by\nadding 0.2 mmol/L [0.8 mg/dL]\nPTH ACTION\n\" Ca reabsorption at distal tubule and\nbone, # PO4 reabsorption at proximal tubule, \"\n1,25(OH)2D3\nMALIGNANCY RELATED MECHANISMS\nlocal osteo\nlytic bone lesions, humoral hypercalcemia of malig\nnancy (PTH related peptide), 1,25(OH)2D3 secretion\n(lymphomas), ectopic hyperparathyroidism (very rare)\nSARCOIDOSIS MECHANISM\nunregulated synth\nesis of 1,25(OH)2D3, the active metabolite of vitamin\nD, in macrophages of granulomas\nCLINICAL FEATURES\nSYMPTOMS\n\u0002 GI\nabdominal pain from constipation, pancreati\ntis, or peptic ulcer disease (moans), N&V\n\u0002 MSK\nbony pain (groans)\n\u0002\nRENAL\ncalculi (stones), polyuria\n\u0002 CNS\ndelirium (psychiatric overtone)\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCa, albumin, Mg, PO4, PTH, ALP, 1,25(OH)2D3,\nlytes, urea, creatinine\nSPECIAL\n\u0002\nMALIGNANCY WORKUP\nconsider PTHrP, serum\nprotein electrophoresis, urine protein electro\nphoresis, PSA, CEA, CA19 9, CA125, CA15 3, CXR\n\u0002\nHYPERPARATHYROIDISM\nWORKUP\nconsider\nU/S\nneck/thyroid and Tc sestamibi parathyroid scan\n\u0002\nFAMILIAL HYPOCALCIURIC HYPERCALCEMIA WORKUP\nconsider 24 h urine Ca and creatinine\n\u0002 MEN2A WORKUP\n24 h urinary metanephrine\n\u0002 ECG\nmay show shortened QT interval\nDIAGNOSTIC ISSUES\nPTH LEVEL\n\" in hyperparathyroidism, \"/N in famil\nial hypocalciuric hypercalcemia, # in vitamin D excess\nor PTHrP\nDISTINGUISHING FEATURES BETWEEN\nIMPORTANT CAUSES OF HYPERCALCEMIA\nPrimary\nPTH\nSarcoidosis\nPTHrP\nFHH\nCa\n\"\"\n\"\n\"\"\n\"\nPO4\n#\n\"\n#\n#\nPTH\n\"\"/N\n#\n#\n\"/N\nPTHrP\n\"\nCalcitriol\n\"\n\"\n\"\n#/N\nUrine Ca\n\"\n\"/N\n\"\n#\nMANAGEMENT\nSYMPTOM CONTROL\nNS 200 500 mL/h IV \u0007 fur\nosemide 20 40 mg IV TID PRN. If Ca is 3.0 mmol/L\n[12 mg/dL] or more give bisphosphonates (pami\ndronate 60 90 mg in 500 mL NS IV over 4 h or\nzoledronate 4 mg in 50 mL NS IV over 15 min). Malig\nnancies may also respond to giving steroids (predni\nsone 60 mg PO daily \u000310 days, hydrocortisone\n200 500 mg IV daily), along with calcitonin 4 8 IU/\nkg IM/SC BID. Note that intranasal calcitonin has not\nbeen shown to be efficacious\nTREAT UNDERLYING CAUSE\nHypercalcemia\n353", "text_length": 3708, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 361/464)", "type": "chunk", "chunk_index": 360, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.746397", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.747152", "status": "complete", "chunks_added": 2}